Pancreatic cancer has a brutal reputation: roughly 9 out of 10 patients don't survive five years past diagnosis. But most of those deaths happen because the cancer is already advanced by the time doctors find it. Now researchers at the University of Pennsylvania and Mayo Clinic have developed a blood test that could change that timeline.
The test combines four protein markers to spot pancreatic ductal adenocarcinoma — the most common form — with 91.9% accuracy in lab studies. More importantly, it catches early-stage cancers 87.5% of the time, the stage when treatment actually works.
How the test works
For years, doctors have used a single marker called CA19-9 to monitor pancreatic cancer patients. But as a screening tool, it's unreliable. It can spike in people with harmless conditions like pancreatitis. Some patients don't produce it at all due to genetics. The new approach ditches reliance on any single marker.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxResearchers studied stored blood samples from pancreatic cancer patients and healthy volunteers, looking for patterns. They found that two proteins — aminopeptidase N (ANPEP) and polymeric immunoglobulin receptor (PIGR) — showed up at higher levels in early-stage cancer cases. When combined with CA19-9 and another existing marker called thrombospondin 2, the four-protein panel became far more accurate.
The test also distinguished cancer from noncancerous pancreatic conditions like chronic pancreatitis, which matters because these diseases can look identical on imaging and confuse simpler tests.
What happens next
This is a lab study, not a screening tool you can get today. The real test comes next: larger studies in actual populations, particularly in people before symptoms appear. Researchers want to know if the test could work as a screening tool for high-risk groups — people with a family history of pancreatic cancer, genetic mutations that increase risk, or a history of pancreatic cysts.
If those studies confirm what the lab work suggests, the timeline shifts. Instead of pancreatic cancer being discovered when it's already stage III or IV, it could be caught when surgery and chemotherapy actually improve survival odds. For a disease where early detection has historically been impossible, that's the difference between a death sentence and a fighting chance.
